Clinical Trial Enzyme Application Targeting Venous Leg Ulcers

Inclusion Criteria: * Male or female patients aged 18 years and older at screening * Patients with at least one defined Venous Leg Ulcer (VLU) suitable for treatment that is no smaller than 2cm2 but no larger than 50cm2 * Presence of devitalised tissue within the reference ulcer suitable for debridement therapy * Confirmed, clinically diagnosed VLU (30 days or more) which has been present for less than 2 years * Willing and able to attend and comply with study visits and study related activities Exclusion Criteria: * Diabetic Foot Ulcer * A clinical history of a bleeding disorder including haemophilia, purpura, or thrombocytopenia * Current or history of use of anti-thrombotic therapy less than 7 days prior to screening. * Stage 4 or 5 chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) less than or equal to 30 mL/min * Reference ulcer has active infection or florid oedema at screening * Oral or intravenous antibiotics for any indication within 72 hours of screening * Reference ulcer has exposed tendons, ligaments, muscle, or bone * Active osteomyelitis, cellulitis or gangrene in either leg * Patients with amputation above a trans metatarsal amputation (TMA) in the target leg * Planned vascular surgery, angioplasty, or thrombolysis procedures within the study period, or 4 weeks before screening